ESTRO 2024 - Abstract Book

S2746

Interdisciplinary - Global health

ESTRO 2024

University) since 2020 and a 3- day theoretical and practical training in PBM at Cancer Sciences School since 2022. Teachers and students of several French speaking countries from both types of training form a professional community involved in the multidisciplinary consultation meeting. We have started clinical and translational research involving PBM (listed in table 2) and also dosimetric studies with the medical physics unit. Two clinical studies involving twenty radiotherapy centers are waiting for financial support from French Health Ministry.

Conclusion:

The photobiomodulation therapy permit in practice to decrease incidence and severity of acute or chronic radiation induced toxicity.The activity of photobiomodulation should be implemented in all public or private radiotherapy center and our experience could be a facilitator toolkit for centers.

Keywords: photobiomodulation, radiation toxicities

References:

Antunes, H.S., Herchenhorn, D., Small, I.A., et al, 2013. Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol 109, 297– 302. Robijns J, Lodewijckx J, Claes S, Van Bever L, Pannekoeke L, Censabella S, et al. 2021, Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial). Radiother Oncol J Eur Soc Ther Radiol Oncol;158:268-75.

De Faria, C.M.G., Barrera-Patiño, C.P., Santana, J.P.P., et al., 2021. Tumor radiosensitization by photobiomodulation. J Photochem Photobiol B 225, 112349.

2271

Mini-Oral

Telemedicine clinical trial on survivors following hadrontherapy: preliminary results (NCT05947149)

Anna Maria Camarda 1 , Carmine Tinelli 2 , Lucia Pia Ciccone 1 , Nadia Facchinetti 3 , Federica Serra 3 , Alberto Iannalfi 1 , Giulia Riva 1 , Barbara Vischioni 1 , Maria Bonora 1 , Sara Ronchi 1 , Rossana Ingargiola 1 , Sara Lillo 1 , Lisa Licitra 4,5 , Ester Orlandi 1 1 National Center for Oncological Hadrontherapy (CNAO), Radiation Oncology, Pavia, Italy. 2 National Center for Oncological Hadrontherapy (CNAO), Scientific Direction Office, Pavia, Italy. 3 National Center for Oncological Hadrontherapy (CNAO), Clinical Trials Center, Pavia, Italy. 4 Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Medical Oncology Head and Neck Cancer Department, Milan, Italy. 5 National Center for Oncological Hadrontherapy (CNAO), Scientific Direction, Pavia, Italy

Purpose/Objective:

Recent advances in cancer treatments have led to more patients living longer with cancer, resulting in an increase of studies focusing on quality of life (QoL) and patient-reported outcomes (PROs) (1). Survivors from head and neck cancers (HNCs), skull base (SBCs) and brain cancers (BCs) differ from common cancers’ survivors by